ReviewAntibodies (Basel, Switzerland)2023

Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics.

F Donelson Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.